Virtu Financial LLC Sells 177,344 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Virtu Financial LLC decreased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 47.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,379 shares of the company’s stock after selling 177,344 shares during the quarter. Virtu Financial LLC’s holdings in Ginkgo Bioworks were worth $335,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Spire Wealth Management bought a new stake in Ginkgo Bioworks during the 4th quarter valued at about $25,000. Prime Capital Investment Advisors LLC bought a new stake in Ginkgo Bioworks during the 4th quarter valued at about $37,000. Smith Salley & Associates lifted its holdings in Ginkgo Bioworks by 100.0% during the 4th quarter. Smith Salley & Associates now owns 24,000 shares of the company’s stock valued at $41,000 after buying an additional 12,000 shares in the last quarter. Pine Valley Investments Ltd Liability Co bought a new stake in Ginkgo Bioworks during the 4th quarter valued at about $50,000. Finally, National Bank of Canada FI raised its holdings in shares of Ginkgo Bioworks by 142.0% in the 4th quarter. National Bank of Canada FI now owns 30,672 shares of the company’s stock valued at $51,000 after purchasing an additional 18,000 shares in the last quarter. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Trading Down 1.8 %

NYSE:DNA opened at $0.42 on Thursday. The company has a market cap of $930.95 million, a PE ratio of -0.96 and a beta of 1.24. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $0.41 and a twelve month high of $2.55. The company’s 50 day moving average is $0.74 and its two-hundred day moving average is $1.13.

Ginkgo Bioworks (NYSE:DNA) last released its earnings results on Thursday, May 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Ginkgo Bioworks had a negative net margin of 409.11% and a negative return on equity of 56.09%. The company had revenue of $37.94 million for the quarter, compared to the consensus estimate of $45.50 million. During the same quarter in the previous year, the firm earned ($0.08) EPS. As a group, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on DNA shares. TD Cowen reduced their price target on shares of Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Morgan Stanley reduced their price target on shares of Ginkgo Bioworks from $2.00 to $1.00 and set an “equal weight” rating for the company in a report on Wednesday, May 15th. BTIG Research lowered shares of Ginkgo Bioworks from a “neutral” rating to a “sell” rating in a report on Wednesday, May 15th. Finally, William Blair lowered shares of Ginkgo Bioworks from a “market perform” rating to an “underperform” rating in a report on Friday, May 10th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $1.90.

Insider Buying and Selling at Ginkgo Bioworks

In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 47,806 shares of Ginkgo Bioworks stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the sale, the insider now directly owns 925,400 shares in the company, valued at approximately $777,336. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 47,806 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the transaction, the insider now directly owns 925,400 shares in the company, valued at $777,336. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Marijn E. Dekkers sold 265,000 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $0.83, for a total transaction of $219,950.00. Following the transaction, the director now owns 5,515,364 shares of the company’s stock, valued at $4,577,752.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 377,415 shares of company stock worth $321,226. Company insiders own 15.05% of the company’s stock.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.